Early Genetic Screening Transforms Lives for Children with Rare Muscle Disease, Parents Advocate for Universal Testing

Driffield, East Yorkshire – The lives of two young siblings, both diagnosed with a severe genetic condition, are unfolding dramatically differently due to varying access to early newborn screening, prompting their parents to champion universal testing. Marley, five, and his four-month-old sister Meadow, both have spinal muscular atrophy (SMA), a progressive muscle-wasting disease that can be fatal if left untreated in its most severe form.

Marley, who received his diagnosis at five months old, faces complex challenges, unable to walk or speak, and requiring constant respiratory support. In stark contrast, Meadow is achieving all developmental milestones for her age, a direct result of receiving life-changing gene therapy shortly after her birth, made possible by immediate screening.

Rosie and Wes, the children’s parents, are at the forefront of a campaign advocating for SMA to be included in routine newborn blood spot tests across the nation. “The sooner you uncover newborn SMA, the sooner a child’s life can be transformed,” Rosie told reporters. She highlighted the profound difference in her children’s futures: “Marley requires extensive daily care due to his complex needs. Meadow, however, is projected to lead a largely normal life, with minimal need for breathing assistance.”

Millenium TV has learned that the couple is supporting SMA UK, a charity urging for the condition to be added to the existing newborn screening panel, which currently checks for ten other serious but rare conditions. At present, SMA screening is only performed if a sibling has already been diagnosed. Experts estimate approximately 47 babies were born with SMA in the UK this year, with roughly one in 40 individuals carrying the altered gene.

The parents vividly recall their world “crashing down” upon Marley’s diagnosis at five months. “Marley needs respiratory support every single day and cannot eat orally, requiring tube feeding,” Rosie explained. “He uses a ventilator at night and cannot walk or talk.” Marley received Zolgensma, a pioneering gene therapy, at 16 months. Millenium TV understands that this drug delivers a healthy gene copy, but its effectiveness is highly time-sensitive, as irreversible neurological damage can occur quickly.

For Meadow, the same therapy was administered within weeks of her birth. Despite the initial difficulty of hearing her daughter’s diagnosis, Rosie is overjoyed by Meadow’s progress. “She is already rolling over from back to front and front to back at four months old,” she shared.

In 2018, the UK National Screening Committee (NSC) initially advised against widespread SMA screening, citing insufficient long-term data on treatment outcomes and cost-effectiveness for the health service. However, the committee has since initiated a review of this decision, acknowledging “significant developments,” including the introduction of new treatments. Further evaluations are underway within the NHS. Meanwhile, a two-year pilot program for universal newborn SMA testing is slated to commence in Scotland in 2026.

Portia Thorman, representing SMA UK, expressed to Millenium TV that it would be “ethically wrong” to delay the implementation of national screening. “Receiving a diagnosis now can be filled with hope,” Thorman stated. “Children are being diagnosed much earlier, and three excellent drugs are working incredibly well. The future for these children is promising.”

Professor Laurent Servais, a leading expert in neuromuscular diseases at the University of Oxford, conducted research into newborn screening models adopted by other nations, including Belgium. “In the US, Europe, Japan, and Australia, every single baby is screened for SMA at birth, even without a family history of the condition,” Professor Servais noted. He emphasized that a similar approach in the UK would enable immediate treatment, fundamentally altering a child’s future. Professor Servais asserts that newborn testing is “extremely easy to implement” and that the treatment’s efficacy would far outweigh the screening costs.

A spokesperson for the Department of Health and Social Care indicated that the UK National Screening Committee has recommended a comprehensive study for newborn SMA screening to gather additional evidence. “This recommendation is currently under consideration, and we are collaborating closely with families and campaigners,” the spokesperson affirmed.

Despite his later diagnosis, Marley has shown remarkable progress through consistent physiotherapy and medication. His mother shared that he can now sit unaided for three minutes, a significant improvement. Marley has also begun attending mainstream school, allowing him to participate alongside his peers. While Rosie and Wes acknowledge Meadow’s early intervention will likely lead to a very different life than Marley’s, they carry a “massive” sense of guilt shared by other SMA families. Yet, Rosie concludes with a message of hope: “If you’ve had a child diagnosed with SMA, it gets better.”